No Data
No Data
Jefferies Initiates EISAI CO LTD(ESALF.US) With Hold Rating, Announces Target Price $44.43
Jefferies analyst Stephen Barker initiates coverage on $EISAI CO LTD(ESALF.US)$ with a hold rating, and sets the target price at $44.43.According to TipRanks data, the analyst has a success rate of 58
Macquarie Initiates EISAI CO LTD(ESALF.US) With Buy Rating, Announces Target Price $61.59
Macquarie analyst Tony Ren initiates coverage on $EISAI CO LTD(ESALF.US)$ with a buy rating, and sets the target price at $61.59.According to TipRanks data, the analyst has a success rate of 54.5%
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Sen. Bernie Sanders (I-Vt.) recently expressed his concerns about the high cost of medical care in the United States, highlighting the financial burden it places on patients.
EISAI CO LTD To Go Ex-Dividend On September 27th, 2024 With 0.704 USD Dividend Per Share
July 9th (Eastern Time) - $EISAI CO LTD(ESALF.US)$ is trading ex-dividend on September 27th, 2024.Shareholders of record on September 30th, 2024 will receive 0.704 USD dividend per share on November 1
EISAI TO BEGIN ENROLLING STUDY IN PATIENTS WITH NARCOLEPSY
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
On Tuesday, the FDA approved Eli Lilly and Co's (NYSE:LLY) Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer's disease.Once-monthly, Kisunla is th
No Data